• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session

    9/30/22 12:06:41 PM ET
    $AEHL
    $AEI
    $AIMD
    $AKRO
    Building Materials
    Industrials
    Real Estate
    Finance
    Get the next $AEHL alert in real time by email

    Gainers

    • Ainos, Inc. (NASDAQ:AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional preclinical study of its low-dose oral interferon formulation against Omicron. The company reported VELDONA formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period.
    • F45 Training Holdings Inc. (NYSE:FXLV) shares jumped 43.1% to $3.1350 after a 13D filing showed the company received a non-binding proposal offer by one or more funds for a value of $4 per share.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) gained 39.9% to $8.03. InMed recently reported a FY22 net loss of $33.17 per share.
    • SOBR Safe, Inc. (NASDAQ:SOBR) jumped 39.3% to $2.6884 after the company announced it signed three reseller agreements with national distributors.
    • MoneyLion Inc. (NYSE:ML) rose 28% to $1.02. MoneyLion responded to Consumer Financial Protection Bureau’s meritless complaint.
    • FingerMotion, Inc. (NASDAQ:FNGR) surged 23.1% to $2.2778.
    • O2Micro International Limited (NASDAQ:OIIM) rose 22.8% to $3.9901 after the company announced it entered into a definitive agreement for a "going private" transaction.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares gained 22.6% to $8.89. The stock has been volatile after the company last week announced a 1-for-15 reverse split and received meeting minutes from the FDA regarding a meeting conducted on August 9, 2022, for IV Tramadol.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) rose 18.9% to $23.11.
    • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) gained 18.8% to $1.77. X4 Pharmaceuticals recently announced data from its Phase 1b trial evaluating mavorixafor in chronic neutropenia.
    • Benson Hill, Inc. (NYSE:BHIL) rose 18.3% to $2.9250 after UBS initiated coverage on the stock with a Buy rating and $5 price target.
    • Tyra Biosciences, Inc. (NASDAQ:TYRA) jumped 17.7% to $10.33.
    • Alset EHome International Inc. (NASDAQ:AEI) gained 17.3% to $0.2299.
    • Snow Lake Resources Ltd. (NASDAQ:LITM) surged 16.7% to $1.8215. Snow Lake Resources issued filing showing the company has requested for withdrawal of registration statement in regards to its previously announced public offering.
    • Nocera, Inc. (NASDAQ:NCRA) jumped 16.2% to $1.58. Nocera recently entered into agreement to acquire 51% controlling interest in iTake Inc. in Taiwan.
    • Ecoark Holdings, Inc. (NASDAQ:ZEST) gained 14.8% to $1.47.
    • SAI.TECH Global Corporation (NASDAQ:SAI) rose 14.6% to $2.59 after dipping 26% on Thursday. SAI.TECH recently announced the launch of new liquid cooling Bitcoin mining infrastructure products.
    • Solid Biosciences Inc. (NASDAQ:SLDB) gained 14.4% to $0.5355 after the company announced acquisition of AavantiBio and a concurrent $75 million private placement.
    • Akero Therapeutics, Inc. (NASDAQ:AKRO) rose 14.3% to $34.06. Akero Therapeutics recently released topline data from HARMONY Phase 2b study of efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).
    • IonQ, Inc. (NYSE:IONQ) gained 13.3% to $5.41after the company announced it secured a contract to provide quantum solutions to the U.S. Air Force Research Lab.
    • Immuneering Corporation (NASDAQ:IMRX) jumped 12.6% to $14.77. Immuneering announced FDA clearance of IND application for Phase 1/2a clinical trial of IMM-1-104 to treat advanced solid tumors with RAS mutations.
    • bluebird bio, Inc. (NASDAQ:BLUE) gained 12.2% to $6.39. bluebird bio recently named Katherine Breedis as interim CFO.
    • Foghorn Therapeutics Inc. (NASDAQ:FHTX) jumped 11.2% to $9.13.
    • MINISO Group Holding Limited (NYSE:MNSO) surged 11% to $5.53. MINISO Group’s board of directors recently authorized and approved a new share repurchase program.
    • Daseke, Inc. (NASDAQ:DSKE) gained 10.5% to $5.41 after the company announced a $40 million stock repurchase program.
    • Iveda Solutions, Inc. (NASDAQ:IVDA) rose 9.9% to $0.67 after declining over 6% on Thursday. Iveda Solutions, last month, announced a $5 million private placement.
    • Kura Oncology, Inc. (NASDAQ:KURA) gained 9.2% to $14.53. Kura Oncology, last month, posted a Q2 loss of $0.52 per share.
    • Paysafe Limited (NASDAQ:PSFE) gained 8.8% to $1.48.
    • Charles River Laboratories International, Inc. (NYSE:CRL) gained 7.6% to $204.46 after Jefferies upgraded the stock from Hold to Buy and announced a $240 price target.
    • WISeKey International Holding AG (NASDAQ:WKEY) rose 7.3% to $1.6101.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) rose 6.2% to $1.54.


    Losers

    • Antelope Enterprise Holdings Limited (NASDAQ:AEHL) shares dipped 36.7% to $0.57 after the company announced pricing of a $1 million registered direct offering.
    • American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) fell 36.4% to $ 0.1899. AVCT announced intent to effect reverse stock split.
    • SHF Holdings Inc (NASDAQ:SHFS) fell 23% to $6.73 after declining 15% on Thursday. Northern Lights Acquisition completed business combination of SHF, Safe Harbor Financial, which offers compliance services to financial institutions that serve the regulated cannabis industry.
    • 5E Advanced Materials Inc. (NASDAQ:FEAM) dropped 22.8% to $10.82.
    • Aterian, Inc. (NASDAQ:ATER) fell 20.3% to $1.5708 after the company priced a 10,526,368 share registered direct offering at $1.90 per share
    • Carnival Corporation (NYSE:CCL) fell 19% to $6.73 after the company reported worse-than-expected Q3 EPS and sales results.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) dropped 17.8% to $0.2951 after the company priced a common stock offering of 20.1 million shares at $0.30 per share.
    • Rent-A-Center Inc (NASDAQ:RCII) fell 17.3% to $18.46 as the company lowered its earnings guidance for the third quarter and named Mr. Fahmi Karam as new Executive Vice President - Chief Financial Officer.
    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) dipped 16.1% to $0.4997.
    • Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares fell 15% to $13.96 after the company announced its REVERSE Phase 3 study of obeticholic acid did not meet its primary endpoint.
    • OpGen, Inc. (NASDAQ:OPGN) fell 15% to $0.3201 after the company announced a $3.38 million registered direct offering.
    • TH International Ltd (NASDAQ:THCH) declined 12.7% to $6.36.
    • Norwegian Cruise Line Holdings Ltd. (NASDAQ:NCLH) dropped 12% to $12.21 in sympathy with Carnival, which fell after the company reported worse-than-expected Q3 financial results.
    • Century Aluminum Company (NASDAQ:CENX) dipped 12% to $5.68 after Wolfe Research downgraded the stock from Peer Perform to Underperform.
    • NIKE, Inc. (NYSE:NKE) fell 10.5% to $85.28. NIKE reported better-than-expected earnings and sales results for its first quarter on Thursday. However, the company reported a rise in quarter-ended inventories and revenue in the Greater China region also declined from a year ago.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) dropped 10.3% to $4.60. Ocular Therapeutix 10%+ owner Summer Road LLC reported purchase of 150,000 at an average price of $4.59 per share in Form 4 filing on Thursday.
    • Royal Caribbean Cruises Ltd. (NYSE:RCL) fell 8.7% to $39.84 in sympathy with Carnival, which fell after the company reported worse-than-expected Q3 financial results.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) fell 5% to $28.69 as the stock pulled back after gaining following FDA approval of RELYVRIO for ALS..
    Get the next $AEHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEHL
    $AEI
    $AIMD
    $AKRO

    CompanyDatePrice TargetRatingAnalyst
    Carnival Corporation
    $CCL
    3/19/2026$31.00Equal-Weight → Overweight
    Morgan Stanley
    Nike Inc.
    $NKE
    3/11/2026$73.00Equal Weight → Overweight
    Barclays
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Tyra Biosciences Inc.
    $TYRA
    2/24/2026Overweight
    Cantor Fitzgerald
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    2/13/2026$20.00Overweight → Neutral
    Analyst
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    2/11/2026$23.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carnival upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Carnival from Equal-Weight to Overweight and set a new price target of $31.00

    3/19/26 8:22:53 AM ET
    $CCL
    Marine Transportation
    Consumer Discretionary

    NIKE upgraded by Barclays with a new price target

    Barclays upgraded NIKE from Equal Weight to Overweight and set a new price target of $73.00

    3/11/26 8:29:15 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target

    Guggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    3/9/26 9:13:19 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHL
    $AEI
    $AIMD
    $AKRO
    SEC Filings

    View All

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:04:40 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:03:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Solid Biosciences Inc.

    S-8 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 4:10:52 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wang Yongping (Alan)

    3 - MINISO Group Holding Ltd (0001815846) (Issuer)

    3/18/26 4:34:15 PM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Xu Lili

    3 - MINISO Group Holding Ltd (0001815846) (Issuer)

    3/18/26 4:23:15 PM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Nahlous Nicole Yvette

    3 - Paysafe Ltd (0001833835) (Issuer)

    3/18/26 4:20:34 PM ET
    $PSFE
    Real Estate

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Teuber William J Jr bought $115,155 worth of shares (3,000 units at $38.38), increasing direct ownership by 47% to 9,413 units (SEC Form 4)

    4 - IonQ, Inc. (0001824920) (Issuer)

    2/27/26 9:55:03 PM ET
    $IONQ
    EDP Services
    Technology

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHL
    $AEI
    $AIMD
    $AKRO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    - Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 - - Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 - - Friedreich's Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events - - CPVT (SGT-501): Clinical s

    3/19/26 4:12:05 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DISTINGUISHED GUEST SPEAKERS TO JOIN SEABOURN CONVERSATIONS ON 2027 WORLD CRUISE

    World-Class Experts, Explorers, and Cultural Figures to Enrich 145-Day Global Journey Aboard Seabourn Quest SEATTLE, March 19, 2026 /PRNewswire/ -- Seabourn, the leader in luxury cruises and expedition travel, has announced a distinguished lineup of speakers joining its acclaimed Seabourn Conversations program for the 2027 World Cruise aboard Seabourn Quest. The 145–day voyage will feature a curated roster of storytellers, adventurers, and thought leaders, who will share insights and perspectives designed to enrich the journey and deepen guests' connection to the destinations they explore.

    3/19/26 2:47:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Princess Cruises Brings Alaska to Life with New North to Alaska Experiences for 2026

    Four New Immersive Onboard Experiences Debut as Princess Prepares for its Largest Alaska Season EverFORT LAUDERDALE, Fla., March 19, 2026 /PRNewswire/ -- In anticipation of the 2026 Alaska season, Princess Cruises, the highest-rated cruise line in Alaska, is debuting four new North to Alaska experiences alongside returning guest favorites. All eight Princess ships sailing in Alaska this season will feature the new programming: Star Princess, Coral Princess, Royal Princess, Ruby Princess, Grand Princess, Emerald Princess, Discovery Princess, and Island Princess. First introduced

    3/19/26 12:00:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Leadership Updates

    Live Leadership Updates

    View All

    DISTINGUISHED GUEST SPEAKERS TO JOIN SEABOURN CONVERSATIONS ON 2027 WORLD CRUISE

    World-Class Experts, Explorers, and Cultural Figures to Enrich 145-Day Global Journey Aboard Seabourn Quest SEATTLE, March 19, 2026 /PRNewswire/ -- Seabourn, the leader in luxury cruises and expedition travel, has announced a distinguished lineup of speakers joining its acclaimed Seabourn Conversations program for the 2027 World Cruise aboard Seabourn Quest. The 145–day voyage will feature a curated roster of storytellers, adventurers, and thought leaders, who will share insights and perspectives designed to enrich the journey and deepen guests' connection to the destinations they explore.

    3/19/26 2:47:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Princess Cruises Announces 2028 World Cruise: 115-Day Global Voyage Visiting 49 Destinations Onboard Coral Princess

    See the World, Unpack Once: 2028 World Cruise Features Maiden Call to Mossel Bay, South Africa and Expanded More Ashore ExperiencesFORT LAUDERDALE, Fla., March 10, 2026 /PRNewswire/ -- Princess Cruises announces its spectacular 2028 World Cruise onboard Coral Princess, a 115-day, globe-spanning journey to 49 destinations across 24 countries and five continents - featuring 39 UNESCO World Heritage Sites, more overnight and late-night stays, and a maiden call to Mossel Bay, South Africa, on sale today. Departing January 3, 2028, roundtrip from Fort Lauderdale, or Los Angeles, the

    3/10/26 2:30:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Paysafe Announces Changes to its Board of Directors

    New appointments bring deep expertise in global payments, digital transformation, marketing, and product innovation Paysafe (NYSE:PSFE), a leading payments platform, today announced the appointment of four new non‑executive directors to its Board, effective February 26, 2026. The new directors bring extensive expertise across global payments, financial services, technology, product innovation, and marketing leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227922419/en/Rupert Keeley Rupert Keeley Rupert Keeley brings significant strategic payments expertise and global regulatory insight to Paysafe. His decades of

    2/27/26 7:00:00 AM ET
    $PSFE
    Real Estate

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Financials

    Live finance-specific insights

    View All

    CARNIVAL CORPORATION & PLC TO HOLD CONFERENCE CALL ON FIRST QUARTER EARNINGS

    MIAMI, March 17, 2026 /PRNewswire/ -- Carnival Corporation & plc ((NYSE/LSE: CCL, NYSE:CUK) has scheduled a conference call with analysts for Friday, March 27, 2026, at 10 a.m. (EDT); 2 p.m. (GMT) to discuss the company's first quarter financial results which are expected to be released that morning. A simulcast of the call will be available via the company's websites at www.carnivalcorp.com and www.carnivalplc.com.About Carnival Corporation & plc Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class cruise lines – AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cru

    3/17/26 9:15:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

    – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with

    3/5/26 6:31:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHL
    $AEI
    $AIMD
    $AKRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MoneyLion Inc.

    SC 13D/A - MONEYLION INC. (0001807846) (Subject)

    12/10/24 5:27:46 PM ET
    $ML
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    12/6/24 9:30:49 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care